• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Migraleve
    / Manon


    Active Ingredient *

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    24

    not in the basket chart 1340 13130

    Related information


    Dosage

    Adults and children from the age of 15: 2 tablets when initial signs of migraine attack appear. Then, as required, 2 tablets every 4 hours up to a maximum of 8 tablets per day.
    Children aged 12-14: 1 tablet when initial signs of migraine attack appear. Then, as required, 1 tablet every 4 hours up to a maximum of 4 tablets per day.
    Do not exceed the recommended dose.
    The form of use: Do not chew or crush! The tablet may be halved. Swallow the medicine with a glass of water.


    Indications

    This medicine is intended for the treatment of migraine attacks, including accompanying symptoms: headaches, nausea, vomiting.


    Contra-Indications

    – If you have not been diagnosed as suffering from migraine.
    – If you have taken another analgetic within the previous 4 hours.
    – If you are breast feeding.
    – If you are concomitantly taking other medicines containing paracetamol.
    – If you are sensitive to Paracetamol or any other ingredient of this medicine.
    – If you are under 12 years old.
    – If you know that you rapidly metabolize codeine (i.e. that you are an ultra-rapid metabolizer) and as such are at serious risk of developing a potentially severe side effect to codeine.
    – If you are under 18 and have recently undergone a tonsillectomy or removal of the adenoids due to obstructive sleep apnea and as such are more susceptible to respiratory problems.


    Special Precautions

    Migrainerus with high blood pressure, history of renal disease.
    See prescribing information for full details.


    Side Effects

    The possibility of antihistamine-type side effects, e.g. drowsiness, should be considered when treating patients involved in hazardous occupations.
    See prescribing information for full details.


    Manufacturer
    Janssen Cilag SA – Val de Reuil, France
    Licence holder
    CLOSE